BARD AI
JF-Expert Member
- Jul 24, 2018
- 3,376
- 8,118
Wanasayansi wamesema aina hiyo mpya ya matibabu ya Saratani ambayo hutumia Virusi vya kawaida kuambukiza na kuharibu Seli Hatari imeonesha ufanisi mkubwa kwa wagonjwa.
Wagonjwa 40 wamefanyiwa majaribio ya kuchomwa Sindano ya Virusi ya RP2 na wengine walipata dawa za kawaida ambapo matokeo yameonesha seli za Saratani zikipasuka na kuharibika na wengine wakipata Kinga imara za mwili.
Wagonjwa watatu kati ya 9 waliopewa RP2 pekee waliona uvimbe wao ukipungua, 7 kati ya 30 ambao walikuwa wamechanganya matibabu pia wamepata nafuu ya ugonjwa huku madhara pekee waliyopata ni uchovu kwa kiasi kidogo.
=============================
A new type of cancer therapy that uses a common virus to infect and destroy harmful cells is showing big promise in early human trials, say UK scientists.
One patient's cancer vanished, while others saw their tumours shrink.
The drug is a weakened form of the cold sore virus - herpes simplex - that has been modified to kill tumours.
Larger and longer studies will be needed, but experts say the injection might ultimately offer a lifeline to more people with advanced cancers.
Krzysztof Wojkowski, a 39-year-old builder from west London, is one of the patients who took part in the ongoing phase one safety trial, run by the Institute of Cancer Research at the Royal Marsden NHS Foundation Trust.
He was diagnosed in 2017 with cancer of the salivary glands, near the mouth. Despite surgery and other treatments at the time, his cancer continued to grow.
"I was told there was no options left for me and I was receiving end-of-life care. It was devastating, so it was incredible to be given the chance to join the trial."
A short course of the virus therapy - which is a specially modified version of the herpes virus which normally causes cold sores - appears to have cleared his cancer.
"I had injections every two weeks for five weeks which completely eradicated my cancer. I've been cancer-free for two years now."
The injections, given directly into the tumour, attacks cancer in two ways - by invading the cancerous cells and making them burst, and by activating the immune system.
About 40 patients have tried the treatment as part of the trial. Some were given the virus injection, called RP2, on its own. Others also received another cancer drug - called nivolumab - as well.
BBC
Wagonjwa 40 wamefanyiwa majaribio ya kuchomwa Sindano ya Virusi ya RP2 na wengine walipata dawa za kawaida ambapo matokeo yameonesha seli za Saratani zikipasuka na kuharibika na wengine wakipata Kinga imara za mwili.
Wagonjwa watatu kati ya 9 waliopewa RP2 pekee waliona uvimbe wao ukipungua, 7 kati ya 30 ambao walikuwa wamechanganya matibabu pia wamepata nafuu ya ugonjwa huku madhara pekee waliyopata ni uchovu kwa kiasi kidogo.
=============================
A new type of cancer therapy that uses a common virus to infect and destroy harmful cells is showing big promise in early human trials, say UK scientists.
One patient's cancer vanished, while others saw their tumours shrink.
The drug is a weakened form of the cold sore virus - herpes simplex - that has been modified to kill tumours.
Larger and longer studies will be needed, but experts say the injection might ultimately offer a lifeline to more people with advanced cancers.
Krzysztof Wojkowski, a 39-year-old builder from west London, is one of the patients who took part in the ongoing phase one safety trial, run by the Institute of Cancer Research at the Royal Marsden NHS Foundation Trust.
He was diagnosed in 2017 with cancer of the salivary glands, near the mouth. Despite surgery and other treatments at the time, his cancer continued to grow.
"I was told there was no options left for me and I was receiving end-of-life care. It was devastating, so it was incredible to be given the chance to join the trial."
A short course of the virus therapy - which is a specially modified version of the herpes virus which normally causes cold sores - appears to have cleared his cancer.
"I had injections every two weeks for five weeks which completely eradicated my cancer. I've been cancer-free for two years now."
The injections, given directly into the tumour, attacks cancer in two ways - by invading the cancerous cells and making them burst, and by activating the immune system.
About 40 patients have tried the treatment as part of the trial. Some were given the virus injection, called RP2, on its own. Others also received another cancer drug - called nivolumab - as well.
BBC
